SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)
Diabetes News
Category: Medication
Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials
Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared to those without PAD, with no increase in MALE (Diabetes, Obesity and Metabolism)
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Empagliflozin may reduce steatosis but not fibrosis risk in individuals with type 2 diabetes and cardiovascular disease. The improvements in cardiorenal outcomes and mortality associated with empagliflozin therapy appear to be independent of steatosis and fibrosis risk (Diabetes, Obesity and Metabolism)
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study
Liraglutide had beneficial actions on glycemic parameters and cardiometabolic risk factors in both non-obese and obese patients with T2DM, with a greater efficacy in the latter (Diabetes Therapy)
Oxurion Announces New Data on THR-149 Phase 2 Clinical Trial (“KALAHARI”) in DME
Post-hoc analysis reveals >9 letter gain in mean BCVA that was maintained for the remaining four months of the trial after the last THR-149 injection with no rescue treatment required
These gains were seen in patients that are part of the 40-50% of DME patients that suboptimally respond to standard of care anti-VEGF therapy (Oxurion)
Metformin and risk of age-related macular degeneration in individuals with type 2 diabetes: a retrospective cohort study
We found no evidence that metformin was associated with risk of AMD in primary care patients requiring treatment for type 2 diabetes (BMJ)
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes
Canagliflozin reduces visceral adipose tissue and improves blood glucose, insulin resistance and systemic inflammation in people with newly-diagnosed type 2 diabetes (BMC Endocrine Disorders volume)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes. The SURPASS-5 Randomized Clinical Trial
Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks (JAMA)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population (The Lancet Diabetes & Endocrinology)
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic “one-size-fits-all” approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications (Metabolic Syndrome and Obesity)
Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
SGLT2i and SGLT2i/GLP-1RA combination regimens may be beneficial in primary prevention of MACCE and HF and GLP-1RA for HF. These data call for primary prevention trials using these agents and their combination (Diabetes Care)
Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation study
Our findings suggest protective association of genetically proxied ACE inhibition with diabetes, while genetic proxies for BBs and CCBs possibly relate to an unfavourable metabolic profile (Diabetologia)
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
The ESC recently added SGLT2 inhibitors to the management guidelines for HFrEF following good outcomes from DAPA-HF [18] and EMPEROR-Reduced [19] over the last 2 years. We hope that further supporting evidence for SGLT2 inhibitors in the management of HFpEF follows with the results of the ongoing DELIVER trial expected soon, and that as a result similar changes to guidelines may be added to support the use of SGLT2 inhibitors in the management of HFpEF (Diabetes Therapy)
ZT-01 – A Novel Somatostatin Receptor Antagonist for Restoring the Glucagon Response to Hypoglycemia in Type 1 Diabetes
We conclude that ZT-01 may be effective in restoring glucagon responses and preventing the onset of hypoglycemia in patients with T1D (Diabetes, Obesity and Metabolism)
ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes
Interest in the potential for precision medicine in the prevention, treatment, and ongoing management of diabetes continues to grow across many of the most important stakeholder groups, including people with diabetes (Diabetes Care)
Insulin-GLP-1 receptor agonist relay and GLP-1 receptor agonist first regimens in individuals with type 2 diabetes: a randomized, open-label trial study
The GLP-1 receptor agonist is overall effective without prior glycemic control with insulin in participants with poorly controlled type 2 diabetes. However, in participants with insulinopenic type 2 diabetes, prior glycemic control with insulin may overcome glucose toxicity-induced GLP-1 resistance (Journal of Diabetes Investigation)
Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
The switch from NPH insulin to Gla-300 improved glycemic control in older patients with T2D and in those with a longer disease duration. Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter disease duration, with significantly greater reductions in the risk of hypoglycemia (Diabetes Therapy)
Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial
(i) At EOS T2DM subjects treated with Triple Therapy had less hepatic steatosis and fibrosis versus Conventional Therapy; (ii) severity of hepatic steatosis and fibrosis both were strongly and inversely correlated with insulin resistance; (iii) changes in liver fibrosis scores (APRI, NFS, FIB-4, AST/ALT ratio) have limited value in predicting response to therapy (Diabetes, Obesity and Metabolism)
Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes
The development of high-dose GLP-1 RAs and dual GLP-1/GIP-RA tirzepatide resulted in increasing numbers of people reaching HbA1c and bodyweight targets, with up to 62% attaining normoglycaemia with 15 mg tirzepatide. Whether this will also translate in better cardiovascular outcomes and will affect treatment guidelines remains to be studied (Diabetes, Obesity and Metabolism)
Combined SGLT-2 and ACE inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial
A distinct RAS modulation by SGLT-2i occurs in diabetic kidney disease reflected by enhancement of the beneficial Angiotensin-(1–7) providing a molecular background for this renoprotective therapeutic approach (Diabetes, Obesity and Metabolism)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 52
- Next Page »